Next report date
Report period
Q4 2023
EPS estimate
−0.43USD
Revenue estimate
—
−210.96 MUSD
60.53 M
Om Immunovant, Inc.
Sektor
Bransch
VD
Peter Salzmann
Webbplats
Huvudkvarter
New York
Employees (FY)
164
Grundat
2018
FIGI
BBG00P5MC0Q8
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
